VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost

The Vanguard Health Care ETF (VHT) offers broader healthcare sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.69%), while the SPDR S&P Biotech ETF (XBI) provides targeted biotech exposure with higher volatility but stronger recent 1-year returns (62.20% vs 13.00%). VHT is better suited for income-seeking investors seeking diversified healthcare exposure, while XBI appeals to aggressive investors seeking biotech-specific growth.

05/28/2026, 8:07 AM • The Motley Fool

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.

IHE (U.S. Pharmaceuticals ETF) significantly outperformed IXJ (Global Healthcare ETF) over the past year, driven largely by GLP-1 drug success, particularly from Eli Lilly. While IHE's concentrated focus on domestic pharma delivered 39.70% returns, IXJ's broader global healthcare approach provided more diversification but only 10% returns. Both funds charge similar fees, making the choice dependent on investor preference for concentration versus diversification.

05/27/2026, 11:17 AM • The Motley Fool

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

The obesity drug market is projected to reach nearly $100 billion by decade's end. While Eli Lilly and Novo Nordisk dominate, two other companies—Viking Therapeutics and AbbVie—are positioned for significant growth. Viking is advancing VK-2735, a dual GLP-1/GIP receptor agonist in phase 3 trials with promising results. AbbVie is developing ABBV-295, a long-acting amylin analog with positive phase 1 data. Both stocks are predicted to potentially double in 2026 based on upcoming trial results and market expansion.

05/26/2026, 4:04 AM • The Motley Fool

The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech

As investors shift from tech stocks to lower-risk investments, three dividend growth stocks are recommended: AbbVie, a Dividend King pharma company with a 3.2% yield and strong new drug pipeline; Procter & Gamble, a consumer staples Dividend King with a 3% yield trading below historical valuations; and Enterprise Products Partners, an energy infrastructure MLP with a 5.5% yield and 27 consecutive years of distribution increases.

05/22/2026, 9:15 PM • The Motley Fool

Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors

Ichnos Glenmark Innovation (IGI) announced ISB 2301, a first-in-class multispecific antibody that targets three tumor-associated antigens and activates both T cells and NK cells for solid tumor treatment. The candidate, developed using IGI's proprietary BEAT® platform, demonstrated favorable safety profiles in preclinical studies and is expected to advance toward clinical trials with an IND submission planned by end of 2026.

05/20/2026, 7:00 AM • GlobeNewswire

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

05/19/2026, 1:00 PM • GlobeNewswire

2 Stocks That Are Much Cheaper Than They Look

AbbVie and CVS Health appear expensive based on trailing P/E multiples (100+ and 42 respectively) due to non-recurring charges that depressed recent earnings. However, their forward P/E multiples (15 and 13) reveal they are actually attractive buys. Both companies offer solid dividend yields and strong fundamentals, making them undervalued when accounting for normalized earnings.

05/19/2026, 9:30 AM • The Motley Fool

2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts

The article highlights two healthcare stocks with high dividend yields that are expected to raise payouts: AbbVie, a pharmaceutical company with 12 blockbuster drugs and Dividend King status, and Medtronic, the largest medical device company with 48 consecutive dividend raises and strong free cash flow generation.

05/19/2026, 6:30 AM • The Motley Fool

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

Oruka Therapeutics reported strong phase 2a trial results for ORKA-001, showing 63.5% PASI 100 response rates compared to Skyrizi's typical 51%, potentially threatening AbbVie's $17.6 billion psoriasis drug. However, the article argues AbbVie remains a solid long-term investment due to its diverse pipeline, other growth drivers like Qulipta and Botox, and its status as a Dividend King.

05/11/2026, 5:15 PM • The Motley Fool

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight

The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.

05/11/2026, 1:00 PM • GlobeNewswire

What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress

Chicago-based Cura Wealth Advisors sold 155,210 shares of Blackstone Mortgage Trust (BXMT) worth approximately $2.99 million in Q1 2026, reducing its position from 1.4% to 0.28% of assets under management. The sale comes as BXMT faces headwinds from office property concerns, despite the company maintaining a 98% performing loan portfolio and an attractive 9.4% dividend yield. The stock has significantly underperformed the S&P 500, which is up 30% while BXMT remains flat over the past year.

05/10/2026, 1:37 PM • The Motley Fool

Want Reliable Dividend Income in May? These 2 Stocks Deliver

The article recommends two dividend stocks for reliable income in May: AbbVie, a Dividend King with 54 consecutive years of dividend increases and a 3.27% yield, and Realty Income, a REIT paying monthly dividends with a 5.09% yield and 31 consecutive years of dividend growth. Both companies demonstrate strong underlying businesses and consistent cash flow generation.

05/06/2026, 4:10 AM • The Motley Fool

Want to Collect a High Dividend Every Month? Invest in These 3 Stocks

The article recommends three high-dividend stocks that pay at different times of the year to generate monthly dividend income: AbbVie (3.3% yield), Medtronic (3.6% yield), and Enbridge (5.2% yield). By staggering their payment schedules across all 12 months, investors can receive consistent monthly cash flow while holding financially strong companies.

05/05/2026, 12:30 PM • The Motley Fool

AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook

AbbVie reported strong Q1 2026 results with revenue of $15 billion, beating expectations of $14.7 billion. The company's immunology drugs Skyrizi and Rinvoq continue to exceed projections, with combined sales now expected to exceed $31 billion in 2026 (accelerated from 2027 guidance). Both drugs have upcoming label expansions and patent protection extending into the 2030s, supporting sustained growth. The stock jumped 3% post-earnings and is down 10% year-to-date, making it an attractive buy-and-hold opportunity given its strong pipeline and Dividend King status.

05/04/2026, 4:30 PM • The Motley Fool

3 of the Best Dividend Stocks to Buy in May 2026

The article recommends three dividend stocks for May 2026: AbbVie (yielding 3.4% with strong growth despite Humira patent loss), Verizon Communications (yielding 5.9% with growth prospects from Frontier acquisition), and Canadian Natural Resources (yielding 3.8% with 26 consecutive years of dividend increases). All three stocks trade at low valuations and offer stable income with growth potential.

05/04/2026, 4:26 PM • The Motley Fool